pharmaceutical-investing Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304
pharmaceutical-investing Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa
Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial
gold-investing Roxgold Announces Interim Results of Bagassi South Infill and Extensional Drilling Program for the QV Prime Structure
Rio Silver Launches Metallurgical Program to De-Risk Processing and Optimize Silver Recoveries at Maria Norte
